RIPK1 and cancer: Conventional bulk sequencing or tissue homogenate assays yield population-averaged signals, potentially obscuring the significant heterogeneity of RIPK1 expression across distinct tumour cell subpopulations (e.g., cancer stem cells, differentially differentiated tumour cells, and immune cells within the tumour microenvironment).